Regulatory agencies in the United States and Europe have released joint "Good AI Practice" guidelines for pharmaceutical research, signalling tighter oversight of algorithmic decisions in clinical studies. Industry leaders say machine‑learning tools can shorten preclinical drug discovery by as much as 70 % and reduce expenses, a finding echoed in a survey of 80 biopharma executives.
Proto Axiom CEO Anthony Liveris said AI can turn searches that formerly took years into processes lasting days. The DeepMind‑developed AlphaFold system, whose creators won the 2024 Nobel Prize in Chemistry, continues to transform protein‑structure prediction and downstream drug design. A recent Nature Communications paper reported an AI‑designed enzyme that reverses molecular ageing markers by up to 50 years, lowering skin glycation levels in 75‑year‑olds to those typical of 30‑year‑olds.
At the same time, commentators note that companies and consultants using AI‑derived insights in human trials may face legal liability. A separate analysis highlights that while AI promises faster vaccine formulation, challenges remain for pathogens with high variability, such as HIV, tuberculosis and malaria.
Entities: AlphaFold · Anthony Liveris · DeepMind · European Medicines Agency · Proto Axiom · U.S. Food and Drug Administration · US and European regulatory agencies
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 4 SOURCES] Large‑scale digital simulations are used to target thousands of genes for new biomedical applications. (article description)
- [● 4 SOURCES] AlphaFold, developed by Google DeepMind, was awarded the 2024 Nobel Prize in Chemistry. (article mentions)
- [● 4 SOURCES] A Nature Communications study engineered an enzyme that reverses molecular ageing markers by up to 50 years, reducing skin glycation in 75‑year‑old donors to levels of 30‑year‑olds. (article summary)
- [● 4 SOURCES] US and European regulatory agencies published joint Good AI Practice guidelines for drug development. (joint guideline release)
- [● 4 SOURCES] Anthony Liveris, CEO of Proto Axiom, said AI can turn a years‑long search into a process that takes days. (direct quote in articles)
- [○ 1 SOURCE] Artificial intelligence is being applied to accelerate vaccine development, offering faster, better, and cheaper formulations, though technical limits remain. (article on AI and vaccine development)
- [● 4 SOURCES] Artificial intelligence can reduce pre‑clinical drug development time and cost by up to 70 %. (survey of biopharma executives cited in articles)
- [● 4 SOURCES] Companies and consultants using AI‑derived insights in human studies may be held legally liable, according to Forbes reporting. (legal liability claim)
- [● 4 SOURCES] A Nature Communications study described an AI‑designed enzyme that can reset molecular ageing markers by up to 50 years, lowering skin glycation in 75‑year‑olds to levels of 30‑year‑olds. (enzyme ageing reversal study)
- [● 4 SOURCES] AlphaFold, developed by DeepMind, was instrumental in protein‑structure prediction and its creators received the 2024 Nobel Prize in Chemistry. (AlphaFold achievement)
- [○ 1 SOURCE] AI can accelerate vaccine development but faces limits with highly variable pathogens such as HIV, tuberculosis and malaria. (vaccine development limitations)
- [● 4 SOURCES] AI could reduce preclinical drug discovery time and cost by up to 70 % according to a survey of 80 biotech leaders. (survey of industry executives)